BioMark Diagnostics Inc.
BMKDF
$0.43
$0.038.48%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 0.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.00% | 0.00% | |||
| SG&A Expenses | -49.77% | 4.36% | |||
| Depreciation & Amortization | -61.36% | 61.15% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.54% | 7.95% | |||
| Operating Income | 31.96% | -8.06% | |||
| Income Before Tax | 47.43% | 21.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 47.43% | 21.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 47.43% | 21.95% | |||
| EBIT | 31.96% | -8.06% | |||
| EBITDA | 32.24% | -8.13% | |||
| EPS Basic | 46.15% | 21.21% | |||
| Normalized Basic EPS | 43.75% | 23.81% | |||
| EPS Diluted | 46.15% | 21.21% | |||
| Normalized Diluted EPS | 43.75% | 23.81% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||